Can Luzsana become Hengrui's "Genentech"?

On May 18, according to Endpoint news, Hengrui Medicine established a wholly-owned subsidiary Luzsana Biotechnology, and Luzsana will become Hengrui Medicine's international operation platform and forward ba.

It is understood that through the partnership with the parent company Hengrui Medicine, Luzsana can evaluate and select assets from Hengrui's existing rich pipeline, covering oncology, cardiovascular, metabolism/diabetes, pain management, immunity, liver and kidney diseases, e.

As a domestic pharmaceutical leader, Hengrui has attracted a lot of attention in recent yea.

Is Luzsana the next 'Genentech'?

Roche invested and controlled Genentech in the 1990s and owned most of Genentech's shar.

As an important innovation platform for Hengrui Medicine's overseas expansion, Luzsana has given considerable market attention to this mod.

It is understood that Luzsana's pipeline products are all from Hengrui, and the primary purpose of its establishment and operation is to accelerate Hengrui's internationalization process through other strategies besides licensing and strategic cooperati.

Currently, Luzsana has offices in Tokyo, Basel, Switzerland, Princeton, New Jersey, and more than 120 employees, led by CEO Scott Filo.

It is worth mentioning that Luzsana's website is still under constructi.

Filosi said in an interview with the media: "The management of Hengrui has been thinking about internationalization for a long time, and they are no strangers to overseas cooperati.

Hengrui's internationalization is further accelerated

In recent years, Hengrui Medicine has made great determination and efforts to promote its internationalization strate.

In addition to the above-mentioned appointment of .

At the same time, clinical trials of innovative drugs are being carried out in an orderly mann.

It is worth noting that on May 12, Hengrui Medicine announced that the company's international multi-center phase III clinical trial (SHR-1210-III) of camrelizumab for injection (PD-1) combined with apatinib table.

Based on this research, the indication of camrelizumab for the treatment of advanced hepatocellular carcinoma has obtained the FDA orphan drug status, and it is expected to enjoy certain policy support in the follow-up research and development and commercialization, making it one step closer to its overseas listing go.